Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Janssen Pharmaceutical K.K.
Memorial Sloan Kettering Cancer Center
University of Washington
Northwestern University
National Cancer Institute (NCI)
Mercy Research
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiation Therapy Oncology Group
Stanford University
National Cancer Institute (NCI)
Mayo Clinic
University of Washington
Medical University of South Carolina
National Cancer Institute (NCI)
Boston Medical Center
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
East and North Hertfordshire NHS Trust
Vanderbilt-Ingram Cancer Center